Odds
Yes50%
Range contracts
Exactly one range settles YES.
Range
Chance
Yes
No
< $5,000
50%
$5,000–$10,000
50%
$5,000–$10,000
50%
$10,000–$15,000
50%
$15,000–$20,000
50%
$20,000–$25,000
50%
$25,000–$30,000
50%
$30,000–$35,000
50%
$35,000–$40,000
50%
$40,000–$45,000
50%
$45,000–$50,000
50%
≥ $50,000
50%
Market details
Status
open
Positions
0
Volume
0 cr
Locks
May 23, 2026
Updated
Jan 29, 2026, 07:41 AM
Rules summary
Resolves YES if the initial U.S. wholesale acquisition cost (WAC) at launch for GTx-104 (nimodipine formulation) is ≥ $5,000/course, using the first publicly available WAC from a sponsor price announcement or a pricing compendium (e.g., Red Book / Medi-Span).
If GTx-104 (nimodipine formulation) does not have an FDA approval for Aneurysmal subarachnoid hemorrhage (aSAH) on or before 2026-05-23, resolves NO.
Reference: https://www.globenewswire.com/news-release/2025/08/27/3139943/0/en/Grace-Therapeutics-Announces-U-S-Food-and-Drug-Administration-Acceptance-for-Review-of-New-Drug-Application-for-GTx-104.html
Range: $5,000-$10,000.
Market context
Launch-WAC market anchored to $5,000/course. Evaluation date: 2026-05-23. Source: https://www.globenewswire.com/news-release/2025/08/27/3139943/0/en/Grace-Therapeutics-Announces-U-S-Food-and-Drug-Administration-Acceptance-for-Review-of-New-Drug-Application-for-GTx-104.html
People are also buying
BrowseVote on range
Community vote50% Yes · 4 votes
Vote